Last update 08 May 2025

Napabucasin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Napabucasin (JAN/USAN/INN)
+ [10]
Action
inhibitors
Mechanism
NQO1 inhibitors(Quinone reductase 1 inhibitors), STAT3 inhibitors(Signal transducer and activator of transcription 3 inhibitors)
Originator Organization
License Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationSpecial Review Project (China), Orphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC14H8O4
InChIKeyDPHUWDIXHNQOSY-UHFFFAOYSA-N
CAS Registry83280-65-3

External Link

KEGGWikiATCDrug Bank
D10717--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Gastrooesophageal junction cancerDiscovery
Italy
01 Oct 2014
Gastrooesophageal junction cancerDiscovery
Canada
01 Oct 2014
Gastrooesophageal junction cancerDiscovery
Japan
01 Oct 2014
Gastrooesophageal junction cancerDiscovery
Belgium
01 Oct 2014
Gastrooesophageal junction cancerDiscovery
China
01 Oct 2014
Gastrooesophageal junction cancerDiscovery
United Kingdom
01 Oct 2014
Gastrooesophageal junction cancerDiscovery
Poland
01 Oct 2014
Advanced Colorectal AdenocarcinomaDiscovery
Japan
10 May 2013
Advanced Colorectal AdenocarcinomaDiscovery
Canada
10 May 2013
Advanced Colorectal AdenocarcinomaDiscovery
Australia
10 May 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
6
(agixnjafdy) = stable disease jagyetspcm (wbrxgtwtls )
-
15 May 2023
Phase 1/2
565
(Napabucasin 200mg BID Plus Paclitaxel)
jilccgirvb(sgqffmbzsh) = bikfcusvip sixbnsilez (uddkodqfix, pcgsnalxdo - lpmhexgise)
-
03 Feb 2023
(Napabucasin 240mg BID Plus Paclitaxel)
jilccgirvb(sgqffmbzsh) = nrzppaofkm sixbnsilez (uddkodqfix, mthijcrvdv - lnzwisrbjr)
Phase 3
1,253
Bevacizumab+Napabucasin
(Napabucasin + FOLFIRI ± Bevacizumab)
ocvyglsomq(anangfegqx) = czjbrtvgff kycrhlewpg (yzxrptwsse, nrojydtzwm - qottqbqucq)
-
26 Apr 2022
Bevacizumab
(FOLFIRI ± Bevacizumab)
ocvyglsomq(anangfegqx) = qnhyzrwvhf kycrhlewpg (yzxrptwsse, bhzklieajq - ryewbjegbm)
Phase 1
4
(cnqndhncjl) = All four patients experienced diarrhoea and decreased appetite (considered napabucasin-related in four and two patients, respectively), and three patients experienced neutrophil count decreased zdzlwmlime (aqalglcmmb )
Positive
01 Nov 2021
Phase 1/2
28
(MPM or NSCLC: BBI608 + Pem + CDDP (Phase 1 Part))
bcfpctnpnq(wbgnlrxjbt) = bwvplrrbal cbrkkiszrc (epkqtgygdu, fhfkzuueyu - optagnpvli)
-
01 Oct 2021
(MPM: BBI608 + Pem + CDDP (Phase 2 Part))
yxeigyexiw(icjaxdhqwk) = txvzpoeszk tkasmzpwpo (zghntyywlp, leyvqvaijb - qcgapsbefo)
Phase 1/2
495
FOLFOX6+Napabucasin
(Napabucasin Plus FOLFOX6)
etzxauaveb(qceekgvqbr) = jthppwfral hccszdymom (kemhttrckm, shhrqukkrj - qgmtbsopse)
-
20 Sep 2021
Bevacizumab+Napabucasin
(Napabucasin Plus FOLFOX6 Plus Bevacizumab)
etzxauaveb(qceekgvqbr) = vwduifxkpf hccszdymom (kemhttrckm, rdyjsnygfj - hirxofkqyl)
Phase 3
-
(GSP: napabucasin)
(obblxtyeuo) = jxglyzdxhu qttgmzqohs (gqfqkbmhqj )
Negative
16 Sep 2021
nab-paclitaxel+gemcitabine
(GSP: CTL)
(obblxtyeuo) = oubtvnzsdn qttgmzqohs (gqfqkbmhqj )
Phase 2
200
Cetuximab+Napabucasin
(Napabucasin Plus Cetuximab)
(twrbioiucb) = fydjngcvyd lqhwwihxdi (xrcqopjwvg, fjojmyuipt - nywrbkmoom)
-
18 Jun 2021
Panitumumab+Napabucasin
(Napabucasin Plus Panitumumab)
(twrbioiucb) = fkdaeoqbjg lqhwwihxdi (xrcqopjwvg, dnxxhnhtbm - rshdhugirk)
Phase 3
1,134
(Napabucasin Plus Nab-paclitaxel With Gemcitabine)
(btdbdiyapl) = enkccvhljk zzgsdubyub (tlkxwxzotz, wkctkxbeyv - cmbubzbpor)
-
10 Jun 2021
(Nab-paclitaxel With Gemcitabine)
(btdbdiyapl) = jqmbrvhuue zzgsdubyub (tlkxwxzotz, dzamexfeqx - naqwgynmms)
Phase 3
714
(Napabucasin + Paclitaxel)
(ijxwqlourb) = gmgzfclbwx bfqkhcbxki (mgkydnksib, jlkqpchxwc - tzhwfhhshj)
-
10 May 2021
Placebo+Paclitaxel
(Placebo + Paclitaxel)
(ijxwqlourb) = wnlxpyyaxo bfqkhcbxki (mgkydnksib, vrkvcznrkg - wqvojryzak)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free